Are you aged 18-30 with Type 1 diabetes and a body mass index ≥27kg/m2?
- Study HIC#:2000035452
- Last Updated:04/13/2025
If you are aged 18-30 with type 1 diabetes for over a year and a body mass index ≥27kg/m2, you may be eligible to participate in a study to see how semaglutide (the study drug) impacts metabolic health in young adults who have both type 1 diabetes (T1D) and an elevated body mass index. This type of medication helps blood sugars, heart, and kidneys in adults with type 2 diabetes (T2D) and is included in comprehensive treatment guidelines for T2D.
After the initial screening, you will be asked to participate in 4 metabolic studies/visits that range from one to seven hours in duration. Some of these visits may be combined. Blood draws and magnetic resonance imaging are involved.
Eligible participants will be randomized into 1 of 2 study groups: active semaglutide (2/3 chance) or placebo (1/3 chance) and have intermittent visits during this 52-week treatment phase.
Compensation up to $1115, including $90 allotted for parking at study sites as needed.
Contact Us
For more information about this study, including how to volunteer, contact:
Rehema Mtawali
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
If you are aged 18-30 with type 1 diabetes for over a year and a body mass index ≥27kg/m2, you may be eligible to participate in a study to see how semaglutide (the study drug) impacts metabolic health in young adults who have both type 1 diabetes (T1D) and an elevated body mass index. This type of medication helps blood sugars, heart, and kidneys in adults with type 2 diabetes (T2D) and is included in comprehensive treatment guidelines for T2D.
After the initial screening, you will be asked to participate in 4 metabolic studies/visits that range from one to seven hours in duration. Some of these visits may be combined. Blood draws and magnetic resonance imaging are involved.
Eligible participants will be randomized into 1 of 2 study groups: active semaglutide (2/3 chance) or placebo (1/3 chance) and have intermittent visits during this 52-week treatment phase.
Compensation up to $1115, including $90 allotted for parking at study sites as needed.
Eligibility Criteria
Aged 18-30 with type 1 diabetes for over a year and a body mass index ≥27kg/m2
